소지환가미방이 고지혈 병리인자 및 동물 병태 모델에 미치는 영향

키워드

참고문헌 (42)

1. 통계청, "2008 한국의 사회지표. 2009년 2월", ~ (2009)
2. Chun, S., "The risk groups for coronary heart disease in Koreans. Assessment by distribution of serum lipid concentrations", Clin Chem Lab Med, 37, pp.969~974 (1999)
3. Kim, J.Q., "National cholesterol treatment guidelines in Korean population - setting-up the cutpoints for high blood cholesterol", J Korean Med Sci., 12, pp.17~22 (1997)
4. National Cholesterol Education Program National Heart, Lung, and Blood Institute National Institutes of Health. Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III), , ~, pp.NIH Publication No. 01-3670 (2001)
5. Grundy, S.M., "Approach to lipoprotein management in 2001 national cholesterol guidelines", Am J Cardiol, 90, pp.11i~21i (2002)
6. Fedder, D.O., "New national cholesterol education program III guidelines for primary prevention lipid-lowering drug therapy", Circulation, 105, pp.152~156 (2002)
7. Chuang, P., "Ezetimibe reduces low-density lipoprotein cholesterol (LDL-C) in renal transplant patients resistant to HMG-CoA reductase inhibitors", Am J Ther., 14(5), pp.438~441 (2007)
8. Adameová, A., "The hypolipidemic effect of a new ACAT inhibitor, VULM 1457, in diabetic-hypercholesterolaemic rats", Pharmazie, 60(9), pp.714~715 (2005)
9. Westerterp, M., "Endogenous apoC-I increases hyperlipidemia in apoE-knockout mice by stimulating VLDL production and inhibiting LPL", J Lipid Res., 247(6), pp.1203~1211 (2006)
10. Uhita, K., "Drug Use Evaluation of Antidyslipidemic Agents at a Community Hospital in Japan", PSJ, 122(7), pp.499~506 (2002)
11. Sato, N., "In vivo and in vitro sevoflurane-induced lipid peroxidation in guinea-pig liver microsomes", 75(6), pp.366~370 (1994)
12. Yang, C.C., "Cardiovascular diseases and the risk of venous thromboembolism: a hospital-based case-control sardy", J Chin Med Assoc., 70(3), pp.103~109 (2007)
13. Kannel, W.B,, "High-density lipoproteins: epidemiologic profile and risks of coronary artery disease", Am J Cardiol,, 52(4), pp.9B~12B (1983)
14. Shipley, M.J., "Does plasma cholesterol concentration predict mortality from coronary heart disease in elderly people? 18 year follow up in Whitehall study", BMJ, 303(6794), pp.89~92 (1991)
15. Miura, S., "Therapies for raising high-density lipoprotein cholesterol", Intern Med., 46(7), pp.339~340 (2007)
16. Schoenhagen, P., "Determinants of arterial wall remodeling during lipid- lowering therapy: serial intravascular ultrasound observations from the Reversal of Atherosclerosis with Aggressive Lipid Lowering Therapy (REVERSAL) trial", Circulation, 113(24), pp.2826~2834 (2006)
17. 良石, "秘方大全(名醫珍藏)" (2006), 北京科學技術出版社
18. Slowing, K., "Study of garlic extracts and fractions on cholesterol plasma levels and vascular reactivity in cholesterol-fed rats", J Nutr, 131(3s), pp.994S~999S (2001)
19. Siegel-Axel, D., "Platelet lipoprotein interplay: trigger of foam cell formation and driver of atherosclerosis", Cardiovasc Res, 78(1), pp.8~17 (2008)
20. Igarashi, K., "Improvement of endothelium-dependent coronary vasodilation after a single LDL apheresis in patients with hypercholesterolemia", J Clin Apher., 19(1), pp.11~16 (2004)
21. Tang, F.T., "Crocetin improves endothelium- dependent relaxation of thoracic aorta in hypercholesterolemic rabbit by increasing eNOS activity", Biochem Pharmacol, 72(5), pp.558~565 (2006)
22. 横山, "冠動脈疾患과 酸化스트레스", pp.131~138 (2003), 炎症
23. 小崎丈太郎, "小山千穂:特集　高脂血症治療の曲がり角　Nikkei Medical 6月号", 60~69 (1997)
24. Fruchart, J.C., "Mode of action of fibrates in the regulation of triglyceride and HDL-cholesterol metabolism", Drugs Today, 42(1), pp.39~64 (2006)
25. Shrestha, S., "A combination therapy including psyllium and plant sterols lowers LDL cholesterol by modifying lipoprotein metabolism in hypercholesterolemic individuals", J Nutr, 136(10), pp.2492~2497 (2006)
26. Frick, M.H., "Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease", N Engl J Med., 317(20), pp.1237~1245 (1987)
27. Tsutsumi, K., "Effects of NO-1886, a lipoprotein lipase promoting agent, on homozygous and heterozygous Watanabe heritable hyperlipidaemic rabbits", Arzneimittelforschung, 50(2), pp.118~121 (2000)
28. Jukema, J.W., "Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderat- ely elevated serum cholesterol levels. in: The Regression Growth Evaluation Statin Study (REGRESS)", Circulation, 91(10), pp.2528~2540 (1995)
29. Sacks, F.M., "The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. in: Cholesterol and Recurrent Events Trial investigators", N Engl J Med., 335(14), pp.1001~1009 (1996)
30. Paoletti, R., "Rosuvastatin is superior to pravastatin and simvastatin in reducing low-density lipoprotein cholesterol, enabling more hypercholesterolemic patients to achieve low-density lipoprotein cholesterol targets" (2001), Am Coll Cardiol Annual Scientific Session
31. 정은아, "가미과루해백황금탕의 항고지혈증 효과", 응용약물학회지, 9, pp.104~111 (2001)
32. Kjorholt, C., "Chronic hyperglycemia, independent of plasma lipid levels, is sufficient for the loss of beta-cell differentiation and secretory function in the db", db mouse model of diabetes, 2005, pp.54(9), 2755~2763
33. Halliwell, B., "Biochemical mechanism accounting for the toxic action of oxygen on living organisms. the key role of superoxide dismutase", Cell. Biol. Int. Rep., 2, pp.11~ (1978)
34. Susan, M.D., "Normobaric oxygen toxicity of the lung", New. Engl. J. Med., 303, pp.76~ (1980)
35. Freman, B.A., "Biology of disease : Free radicals and tissue injury", Lab. Invest., 47, pp.412~ (1982)
36. Vaziri, N.D., "Up-regulation of acyl-coenzyme A:cholesterol acyltransferase (ACAT) in nephrotic syndrome", Kidney Int., 61(5), pp.1769~1775 (2002)
37. Vaziri, N.D., "ACAT inhibition reverses LCAT deficiency and improves plasma HDL in chronic renal failure", Am J Physiol Renal Physiol, 287(5), pp.F1038~F1043 (2004)
38. Zoltowska, M., "Bile duct cells: a novel in vitro model for the study of lipid metabolism and bile acid production", Am J Physiol., 276, pp.G407~G414 (1999)
39. Liang, K., "HMG-CoA reductase inhibition reverses LCAT and LDL receptor deficiencies and improves HDL in rats with chronic renal failure", Am J Physiol Renal Physiol, 288(3), pp.F539~F544 (2005)
40. Roberts, C.K., "HMG-CoA reductase, cholesterol 7alpha-hydroxylase, LDL receptor, SR-B1, and ACAT in diet-induced syndrome X", X.Kidney Int., 66(4), pp.1503~1511 (2004)
41. Bocan, T.M., "The combined effect of inhibiting both ACAT and HMG-CoA reductase may directly induce atherosclerotic lesion regression", Atherosclerosis, 157(1), pp.97~105 (2001)
42. Lee, M.K., "Naringenin 7-O-cetyl ether as inhibitor of HMG-CoA reductase and modulator of plasma and hepatic lipids in high cholesterol-fed rats", Bioorg Med Chem, 11(3), pp.393~398 (2003)

관련 논문AI추천